• FDA Expands Pembrolizumab Approval for Advanced Melanoma

    1 month ago - By Medscape

    The expanded approval is for the adjuvant treatment of advanced melanoma after complete resection in patients aged 12 years and older.
    Medscape Medical News
    Read more ...

     

  • FDA approves adjuvant Keytruda for certain adults, children with stage IIB, IIC melanoma

    FDA approves adjuvant Keytruda for certain adults, children with stage IIB, IIC melanoma

    1 month ago - By Healio

    The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.
    The agency also expanded the indication for adjuvant pembrolizumab , an anti-PD-1 therapy, to include children aged 12 years or older with stage III melanoma following complete resection.
    “The standard of care for patients with resected stage IIB and IIC melanoma has been observation, despite the fact that for these patients, the risk recurrence is nearly the same as for patients with later-stage disease, for whom
    Read more ...